Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection

Tripp, Ralph A.; Bakre, Abhijeet

doi:10.1007/82_2017_32

Cited by 4 publications

(4 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The world hardly learns to deal with a virus when new emerges and threatens the future of humanity. A similar situation arises when a new strain of coronavirus (CoV) not previously identified in humans was reported last year (2019) [1]. Positive-sense RNA viruses called corona viruses belong to the Coronaviridae family that are distributed broadly among human and mammals.…”

Section: Introductionmentioning

confidence: 75%

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Qamar¹,

Rehman

Ashfaq

et al. 2020

Preprint

View full text Add to dashboard Cite

1Coronavirus disease 2019 (COVID-19) associated pneumonia caused by severe acute respiratory 2 coronavirus 2 (SARS-COV-2) was first reported in Wuhan, China in December 2019. Till date, 3 no vaccine or completely effective drug is available for the cure of COVID-19. Therefore, an 4 effective vaccine against SARS-COV-2 is needed to be design. This study was conducted to 5 design an effective multi-epitope vaccine (MEV) against SARS-COV-2. Seven antigenic 6 proteins were taken as a target and epitopes (B cell, IFNγ and T cell) were predicted. Highly 7 antigenic and overlapping epitopes were shortlisted. Selected T cell epitopes indicated significant 8 interactions with the HLA-binding alleles and 99.29% coverage of the world's population. 9 Finally, 505 amino acids long MEV was designed by connecting sixteen MHC class I and twelve 1 0 MHC class II epitopes with suitable linkers and adjuvant. Linkers and adjuvant were added to 1 1 enhance the immunogenicity response of the vaccine. The allergenicity, physiochemical 1 2 properties, antigenicity and structural details of MEV were analyzed in order to ensure safety and 1 3 immunogenicity. MEV construct was non-allergenic and antigenic. Molecular docking 1 4 demonstrated a stable and strong binding affinity of MEV with TLR3 and TLR8. Codon 1 5 optimization and in silico cloning ensured increased expression in the Escherichia coli K-12 1 6system. However, to ensure its safety and immunogenic profile, the proposed vaccine needs to be 1 7 experimentally validated. 1 8

show abstract

Section: Introductionmentioning

confidence: 75%

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Qamar¹,

Rehman

Ashfaq

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Viruses are dangerous pathogens and can cause irreversible losses to human lives and economy. The world hardly learns to deal with a virus when new emerges and threatens the future of humanity [ 1 ]. A similar situation arises when a new strain of coronavirus (CoV) not previously identified in humans was reported last year (2019).…”

Section: Introductionmentioning

confidence: 99%

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory coronavirus 2 (SARS-COV-2) is a significant threat to global health security. Till date, no completely effective drug or vaccine is available to cure COVID-19. Therefore, an effective vaccine against SARS-COV-2 is crucially needed. This study was conducted to design an effective multiepitope based vaccine (MEV) against SARS-COV-2. Seven highly antigenic proteins of SARS-COV-2 were selected as targets and different epitopes (B-cell and T-cell) were predicted. Highly antigenic and overlapping epitopes were shortlisted. Selected epitopes indicated significant interactions with the HLA-binding alleles and 99.93% coverage of the world’s population. Hence, 505 amino acids long MEV was designed by connecting 16 MHC class I and eleven MHC class II epitopes with suitable linkers and adjuvant. MEV construct was non-allergenic, antigenic, stable and flexible. Furthermore, molecular docking followed by molecular dynamics (MD) simulation analyses, demonstrated a stable and strong binding affinity of MEV with human pathogenic toll-like receptors (TLR), TLR3 and TLR8. Finally, MEV codons were optimized for its in silico cloning into Escherichia coli K-12 system, to ensure its increased expression. Designed MEV in present study could be a potential candidate for further vaccine production process against COVID-19. However, to ensure its safety and immunogenic profile, the proposed MEV needs to be experimentally validated.

show abstract

“…It has been reported that ncRNAs can affect different stages of the viral cycle and the host's immune responses. In return, viruses regulate ncRNA expression to facilitate their own replication cycle 55‐57 . Recently, it has been observed that some ncRNAs can target the genome or some genes of SARS‐CoV‐2 58–60 .…”

Section: Discussionmentioning

confidence: 99%

Analyzing the expression pattern of the noncoding RNAs (HOTAIR, PVT‐1, XIST, H19, and miRNA‐34a) in PBMC samples of patients with COVID‐19, according to the disease severity in Iran during 2022–2023: A cross‐sectional study

Khanaliha,

Sadri Nahand,

Khatami

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and aimsMicroRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are well‐known types of noncoding RNAs (ncRNAs), which have been known as the key regulators of gene expression. They can play critical roles in viral infection by regulating the host immune response and interacting with genes in the viral genome. In this regard, ncRNAs can be employed as biomarkers for viral diseases. The current study aimed to evaluate peripheral blood mononuclear cell (PBMC) ncRNAs (lncRNAs‐homeobox C antisense intergenic RNA [HOTAIR], ‐H19, X‐inactive‐specific transcript [XIST], plasmacytoma variant translocation 1 [PVT‐1], and miR‐34a) as diagnostic biomarkers to differentiate severe COVID‐19 cases from mild ones.MethodsCandidate ncRNAs were selected according to previous studies and assessed by real‐time polymerase chain reaction in the PBMC samples of patients with severe coronavirus disease 2019 (COVID‐19) (n = 40), healthy subjects (n = 40), and mild COVID‐19 cases (n = 40). Furthermore, the diagnostic value of the selected ncRNAs was assessed by analyzing the receiver‐operating characteristic (ROC).ResultsThe results demonstrated that the expression pattern of the selected ncRNAs was significantly different between the studied groups. The levels of HOTAIR, XIST, and miR‐34a were remarkably overexpressed in the severe COVID‐19 group in comparison with the mild COVID‐19 group, and in return, the PVT‐1 levels were lower than in the mild COVID‐19 group. Interestingly, the XIST expression level in men with severe COVID‐19 was higher compared to women with mild COVID‐19. ROC results suggested that HOTAIR and PVT‐1 could serve as useful biomarkers for screening mild COVID‐19 from severe COVID‐19.ConclusionsOverall, different expression patterns of the selected ncRNAs and ROC curve results revealed that these factors can contribute to COVID‐19 pathogenicity and can be considered diagnostic markers of COVID‐19 severe outcomes.

show abstract

Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection

Cited by 4 publications

References 227 publications

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches

Analyzing the expression pattern of the noncoding RNAs (HOTAIR, PVT‐1, XIST, H19, and miRNA‐34a) in PBMC samples of patients with COVID‐19, according to the disease severity in Iran during 2022–2023: A cross‐sectional study

Contact Info

Product

Resources

About